A reversible metabolic stress-sensitive regulation of CRMP2A orchestrates EMT/stemness and increases metastatic potential in cancer

Cell Rep. 2022 Mar 15;38(11):110511. doi: 10.1016/j.celrep.2022.110511.

Abstract

An epithelial-to-mesenchymal transition (EMT) phenotype with cancer stem cell-like properties is a critical feature of aggressive/metastatic tumors, but the mechanism(s) that promote it and its relation to metabolic stress remain unknown. Here we show that Collapsin Response Mediator Protein 2A (CRMP2A) is unexpectedly and reversibly induced in cancer cells in response to multiple metabolic stresses, including low glucose and hypoxia, and inhibits EMT/stemness. Loss of CRMP2A, when metabolic stress decreases (e.g., around blood vessels in vivo) or by gene deletion, induces extensive microtubule remodeling, increased glutamine utilization toward pyrimidine synthesis, and an EMT/stemness phenotype with increased migration, chemoresistance, tumor initiation capacity/growth, and metastatic potential. In a cohort of 27 prostate cancer patients with biopsies from primary tumors and distant metastases, CRMP2A expression decreases in the metastatic versus primary tumors. CRMP2A is an endogenous molecular brake on cancer EMT/stemness and its loss increases the aggressiveness and metastatic potential of tumors.

Keywords: cytoskeleton; metabolism; metastasis; microtubule; mitochondria; stress.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Epithelial-Mesenchymal Transition / genetics
  • Humans
  • Intercellular Signaling Peptides and Proteins / metabolism*
  • Male
  • Neoplastic Stem Cells / metabolism
  • Nerve Tissue Proteins / metabolism*
  • Prostatic Neoplasms* / pathology
  • Semaphorin-3A* / metabolism
  • Stress, Physiological

Substances

  • Intercellular Signaling Peptides and Proteins
  • Nerve Tissue Proteins
  • Semaphorin-3A
  • collapsin response mediator protein-2

Grants and funding